Market closedNon-fractional

ImmunityBio/IBRX

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About ImmunityBio

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.

Ticker

IBRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

San Diego, United States

Employees

628

ImmunityBio Metrics

BasicAdvanced
$4.3B
Market cap
-
P/E ratio
-$1.05
EPS
-0.23
Beta
-
Dividend rate
$4.3B
-0.23
3.641
3.211
-128.614
-129.587
-2.52%
-57.95%
98.37%
11,660.38
-6.04
-5.9
-8.53
-48.46%
-0.05%
-19.50%
14.65%

What the Analysts think about ImmunityBio

Analyst Ratings

Majority rating from 2 analysts.
Buy

ImmunityBio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-100.00%
Net income
-$134M
-42.52%
Profit margin
0.00%
-100.00%

ImmunityBio Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 25.00%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.32
-$0.19
-$0.35
-$0.20
-
Expected
-$0.24
-$0.26
-$0.18
-$0.16
-$0.17
Surprise
36.17%
-25.49%
94.44%
25.00%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for ImmunityBio stock?

ImmunityBio (IBRX) has a market cap of $4.3B as of July 04, 2024.

What is the P/E ratio for ImmunityBio stock?

The price to earnings (P/E) ratio for ImmunityBio (IBRX) stock is 0 as of July 04, 2024.

Does ImmunityBio stock pay dividends?

No, ImmunityBio (IBRX) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next ImmunityBio dividend payment date?

ImmunityBio (IBRX) stock does not pay dividends to its shareholders.

What is the beta indicator for ImmunityBio?

ImmunityBio (IBRX) has a beta rating of -0.23. This means that it has an inverse relation to market volatility.

Buy or sell ImmunityBio stock

Buy or sell ImmunityBio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing